Vicore Pharma Holding AB

NASDAQ:VCRE

Medical - Pharmaceuticals

Healthcare
$9.90 -1.66%

-$0.24 today

Market cap
$279.65M
Beta
0.15

Volume 0.00M

Average 0.26M

VCRE Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Vicore Pharma Holding ABNASDAQ: VCRE

Operating Income · Q2 FY2026 · quarter ended Jun 2026

Operating income remains negative

Q2 FY2026 operating income was -SEK 15.48M, compared with -SEK 111.17M a year earlier. Trailing-twelve-month operating income was -SEK 285.35M.

Context

  • Operating income amounted to 11905.8% of revenue in FY2025, up 11731.7 pp from a year earlier.
  • Operating income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 9 analysts of -SEK 44.59M (+90.2%) for the fiscal year ending Dec 2026, a step up from the -138.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-SEK 15.48M+87.5% QoQ
Last fiscal yearDec 2025
-SEK 454.45M-138.7% YoY
LTMJun 2026
-SEK 285.35M+26.7% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+86.1%-20.0%-106.1 pp
1 year-138.7%+90.2%+228.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

SEK · from the income statement

Latest · FY2025
(454.45M) SEK
Year-over-year change
-138.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How VCRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +26.7% is the lowest of 2, against a peer median of +222.0%.
  • Operating income amounts to 21455.4% of revenue for VCRE, versus a peer median of 37.4%.
VCRE Competitors
Operating Income for VCRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LQDALiquidia CorporationLTM Jun 2026$168.58M USD+222.0%—37.4%
VCREVicore Pharma Holding ABLTM Jun 2026-SEK 285.35M SEK+26.7%—21455.4%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding VCRE) —+222.0%—37.4%

Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

SEK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000109.35M3.82M
Cost of Revenue3.58M0000
Gross Profit(3.58M)00109.35M3.82M
Gross Margin———100.0%100.0%
Research & Development30.05M249.97M276.29M249.26M390.35M
Selling, General & Admin2.39M37.53M44.6M50.44M67.91M
Operating Expenses32.59M290.73M321.51M299.71M458.26M
Depreciation & Amortization371.33K3.61M3.42M2.24M0
EBITDA(32.07M)(285.19M)(307.9M)(166.64M)(477.41M)
EBITDA Margin———-152.4%-12507.6%
Operating Income(32.59M)(290.73M)(321.51M)(190.36M)(454.45M)
Operating Margin———-174.1%-11905.8%
Interest Income70.2K913K10.54M21.08M23.89M
Interest Expense08K2K8K60K
Other Income / Expenses(211.92K)1.92M10.18M21.47M(23.03M)
Income Before Tax(32.8M)(288.81M)(311.33M)(168.89M)(477.47M)
Pre-Tax Margin———-154.5%-12509.1%
Income Tax Expense(252.7K)(384K)(384K)(256K)0
Net Income(294.97M)(288.42M)(310.94M)(168.63M)(477.47M)
Net Margin———-154.2%-12509.1%
EPS (Basic)(0.47)(38.82)(31.80)(12.30)(19.90)
EPS (Diluted)(0.47)(38.82)(31.80)(12.30)(19.90)
Weighted Avg Shares69.68M7.42M9.66M13.68M23.99M
Weighted Avg Shares (Diluted)69.68M7.42M9.66M13.68M23.99M

Vicore Pharma Holding AB

NASDAQ:VCRE

Intrinsic Alpha fair value

Locked

Current Price

$9.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.